Open an account

Anebulo Pharmaceuticals

ANEB · OTC

$0.295+$0.2943 (+42042.86%)TodayMarket closed ·
No price history for this range.

About ANEB

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. The company is headquartered in Lakeway, Texas and currently employs 2 full-time employees. The company went IPO on 2021-05-07. The company is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous administration. Selonabant is intended to rapidly reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. The company is also prioritizing the advancement of a selonabant intravenous (IV) formulation as a potential treatment for pediatric patients with cannabis-induced CNS depression.

Employees
2
Headquarters
Lakeway, Texas
Listed
May 7, 2021
Sector
Health Care
Industry
Pharmaceuticals
Website
anebulo.com

ANEB key statistics

Market cap
28.55K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
299
Volume
100
Open price
$0.295
High today
$0.295
Low today
$0.295
52 Week high
$2.85
52 Week low
$0.0004

Anebulo Pharmaceuticals (ANEB) at a glance

As of Oct 20, 2026, Anebulo Pharmaceuticals (ANEB) shares are priced at $0.295, giving the company a market cap of 28.55K and a price-to-earnings ratio of 0.00.

Volume so far is 100 shares, below the average of 299 shares a day.

Over the past year Anebulo Pharmaceuticals has ranged from $0.0004 to $2.85, and now sits 10% of the way up that range.

Anebulo Pharmaceuticals met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.05 per share against an estimate of -$0.1326.

ANEB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 55.3% on average.

  1. Q3 FY24: reported -$0.06 per share against an estimate of -$0.1204
  2. Q4 FY24: reported -$0.05 per share against an estimate of -$0.1331
  3. Q1 FY25: reported -$0.08 per share against an estimate of -$0.051
  4. Q2 FY25: reported -$0.09 per share against an estimate of -$0.0816
  5. Q3 FY25: reported -$0.05 per share against an estimate of -$0.1224
  6. Q4 FY25: reported -$0.05 per share against an estimate of -$0.0816
  7. Q1 FY26: reported -$0.05 per share against an estimate of -$0.1224
  8. Q2 FY26: reported -$0.05 per share against an estimate of -$0.1326

ANEB news

  • Press releaseBusiness Wire

    Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • Press releaseBusiness Wire

    Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC

  • Press releaseBusiness Wire

    Anebulo Pharmaceuticals Announces Final Results of Tender Offer

  • Press releaseBusiness Wire

    Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Avi Kapoor

    Crude Oil Jumps 2%; Chicago Fed National Activity Index Improves Slightly In September

  • Avi Kapoor

    US Stocks Higher; Nasdaq Surges Over 100 Points

Similar companies

Companies in the same industry as Anebulo Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.